MCID: VST006
MIFTS: 28

Vestibulocochlear Nerve Disease

Categories: Ear diseases, Neuronal diseases

Aliases & Classifications for Vestibulocochlear Nerve Disease

MalaCards integrated aliases for Vestibulocochlear Nerve Disease:

Name: Vestibulocochlear Nerve Disease 12 15
Vestibulocochlear Nerve Diseases 45 74
Cochlear Nerve Diseases 74
Acoustic Nerve Disease 12

Classifications:



External Ids:

Disease Ontology 12 DOID:12657
ICD9CM 36 388.5
MeSH 45 D000160
NCIt 51 C27207
SNOMED-CT 69 77949003
ICD10 34 H93.3 H93.3X

Summaries for Vestibulocochlear Nerve Disease

MalaCards based summary : Vestibulocochlear Nerve Disease, also known as vestibulocochlear nerve diseases, is related to vestibular neuronitis, and has symptoms including tinnitus and earache. An important gene associated with Vestibulocochlear Nerve Disease is RTEL1 (Regulator Of Telomere Elongation Helicase 1). The drugs Methylprednisolone and Prednisolone phosphate have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and endothelial, and related phenotypes are Synthetic lethal with vaccinia virus (VACV) infection and embryo

Wikipedia : 77 The vestibulocochlear nerve (auditory vestibular nerve), known as the eighth cranial nerve, transmits... more...

Related Diseases for Vestibulocochlear Nerve Disease

Diseases related to Vestibulocochlear Nerve Disease via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 vestibular neuronitis 8.9 CACNA1A LMX1A PIR RTEL1 SALL1

Symptoms & Phenotypes for Vestibulocochlear Nerve Disease

UMLS symptoms related to Vestibulocochlear Nerve Disease:


tinnitus, earache

GenomeRNAi Phenotypes related to Vestibulocochlear Nerve Disease according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with vaccinia virus (VACV) infection GR00362-A 8.8 CACNA1A PIR SALL1

MGI Mouse Phenotypes related to Vestibulocochlear Nerve Disease:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 embryo MP:0005380 8.92 LMX1A PIR RTEL1 SALL1

Drugs & Therapeutics for Vestibulocochlear Nerve Disease

Drugs for Vestibulocochlear Nerve Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 101)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Not Applicable 83-43-2 6741
2
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Not Applicable 302-25-0
3
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Not Applicable 2921-57-5
4
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Not Applicable 50-24-8 5755
5
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
6
Prednisolone hemisuccinate Experimental Phase 4,Phase 3,Not Applicable 2920-86-7
7 Anti-Infective Agents Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
8 Gentamicins Phase 4,Not Applicable
9 Anti-Bacterial Agents Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
10 Neuroprotective Agents Phase 4,Phase 3,Not Applicable
11 glucocorticoids Phase 4,Phase 3,Phase 2,Not Applicable
12 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Not Applicable
13 Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
14 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Not Applicable
15 Antiemetics Phase 4,Phase 3,Not Applicable
16 Gastrointestinal Agents Phase 4,Phase 3,Not Applicable
17 Prednisolone acetate Phase 4,Phase 3,Not Applicable
18 Autonomic Agents Phase 4,Phase 3,Not Applicable
19 Hormones Phase 4,Phase 3,Phase 2,Not Applicable
20 Protective Agents Phase 4,Phase 3,Not Applicable
21 Methylprednisolone Acetate Phase 4,Phase 3,Not Applicable
22 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
23 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
24 Betamethasone Valerate Phase 4 2152-44-5
25 Betamethasone-17,21-dipropionate Phase 4
26 Anti-Asthmatic Agents Phase 4,Phase 3
27 Betamethasone sodium phosphate Phase 4
28 Respiratory System Agents Phase 4,Phase 3
29 Betamethasone benzoate Phase 4
30 Ophthalmic Solutions Phase 4
31
Ethanol Approved Phase 3 64-17-5 702
32
Cilostazol Approved, Investigational Phase 3 73963-72-1 2754
33
Coenzyme Q10 Approved, Investigational, Nutraceutical Phase 3 303-98-0 5281915
34 Ginkgo Phase 3
35 Nutrients Phase 3
36 Micronutrients Phase 3
37 Vitamins Phase 3
38 Complement System Proteins Phase 3
39 Ubiquinone Phase 3
40 Lecithin Phase 3
41 Trace Elements Phase 3
42 Fibrinolytic Agents Phase 3,Phase 2
43 Platelet Aggregation Inhibitors Phase 3,Phase 2
44 Vasodilator Agents Phase 3,Phase 2
45 Phosphodiesterase Inhibitors Phase 3
46 Bronchodilator Agents Phase 3
47 Phosphodiesterase 3 Inhibitors Phase 3
48
Sirolimus Approved, Investigational Phase 2,Phase 1,Early Phase 1 53123-88-9 46835353 5284616 6436030
49
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
50
Everolimus Approved Phase 2,Phase 1,Early Phase 1 159351-69-6 70789204 6442177

Interventional clinical trials:

(show top 50) (show all 92)
# Name Status NCT ID Phase Drugs
1 Gentamicin Treatment Prior to Schwannoma Surgery - Residual Function Unknown status NCT02379754 Phase 4 Gentamicins
2 Acute Unilateral Vestibulopathy and Corticosteroid Treatment Recruiting NCT02912182 Phase 4 Betamethasone;Placebo;Prednisolone
3 Gentamicin Treatment Prior to Schwannoma Surgery - No Residual Function Recruiting NCT02415257 Phase 4 Gentamicin
4 Cacicol20® in Corneal Wound Healing and Nerve Regeneration After Phototherapeutic Keratectomy Terminated NCT02373397 Phase 4
5 Stereotactic Radiation in Vestibular Schwannoma Unknown status NCT01449604 Phase 3
6 The Efficacy of Steroid Therapy in Vestibular Neuritis Completed NCT02098330 Phase 3 Ginkgo biloba & Methylprednisolone;Ginkgo biloba
7 Evolution of Albumin on AOA1 Patients Supplemented With Coenzyme Q10 Completed NCT02333305 Phase 3
8 Cyberknife Radiosurgery for Patients With Neurinomas Recruiting NCT02055859 Phase 3
9 Effect of Renexin Tablet in Patients With Recurrent Vestibulopathy Terminated NCT01895400 Phase 3 Renexin (cilostazol 100mg + gingko biloba extract 80 mg);Placebo
10 Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Unknown status NCT02934256 Phase 2 Icotinib
11 Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients Completed NCT01490476 Phase 2 RAD001
12 Complementary/Alternative Medicine for Abnormality in the Vestibular (Balance) System Completed NCT00032383 Phase 1, Phase 2
13 Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Completed NCT02104323 Phase 2 Endostatin
14 Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2 Completed NCT01419639 Phase 2 Everolimus (RAD001) , Afinitor®
15 Prednisone Treatment for Vestibular Neuronitis Completed NCT00271791 Phase 2 Prednisone;Prednisone
16 Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2) Completed NCT01207687 Phase 2
17 Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Completed NCT00973739 Phase 2 Lapatinib
18 Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2 Completed NCT00004437 Phase 2
19 RGD PET/MRI in Sporadic Vestibular Schwannoma Recruiting NCT03393689 Phase 2 One injection of 68Ga-NODAGA-E[c(RGDyK)]2
20 Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors Recruiting NCT03095248 Phase 2 Selumetinib
21 Study of Aspirin in Patients With Vestibular Schwannoma Recruiting NCT03079999 Phase 2 Aspirin;Placebo
22 Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma Recruiting NCT01199978 Phase 2
23 AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas Active, not recruiting NCT02831257 Phase 2 AZD2014
24 Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas Active, not recruiting NCT02129647 Phase 2 Axitinib
25 Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas Active, not recruiting NCT01767792 Phase 2 Bevacizumab
26 Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma Active, not recruiting NCT01345136 Phase 2 RAD001, everolimus
27 Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas Active, not recruiting NCT01125046 Phase 2
28 AM-125 in the Treatment of Acute Peripheral Vertigo Following Vestibular Schwannoma Resection Not yet recruiting NCT03908567 Phase 2 Intranasal Drug;Oral Tablet
29 Incremental Velocity Error as a New Treatment in Vestibular Rehabilitation Not yet recruiting NCT03846830 Phase 2
30 A Study of Nilotinib in Growing Vestibular Schwannomas Terminated NCT01201538 Phase 2 Nilotinib
31 PTC299 for Treatment of Neurofibromatosis Type 2 Terminated NCT00911248 Phase 2 PTC299
32 RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Completed NCT01119599 Phase 1 Gamma-Secretase Inhibitor RO4929097;Temozolomide
33 An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors Completed NCT00030043 Phase 1
34 Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease Recruiting NCT01552434 Phase 1 Temsirolimus;Valproic Acid
35 Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Vestibular Schwannoma Suspended NCT01083966 Phase 1 Bevacizumab (Avastin)
36 Characterisation of Cortical Vestibular Evoked Potentials (C-VEPs) Unknown status NCT02463695 Not Applicable
37 Response Prediction After GKS in Patients With Vestibular Schwannoma Using DCE MR Imaging Unknown status NCT03097822
38 The Role of Corticosteroids and Vestibular Exercises in Recovery of Vestibular Neuritis Unknown status NCT01231009 Early Phase 1 Corticosteroids
39 Preoperative Vestibular Rehabilitation Effectiveness After Vestibular Schwannoma Surgery Unknown status NCT02275325 Not Applicable
40 Effect of Implant Position on Magnetic Resonance Image Distortion Unknown status NCT02246231 Not Applicable
41 Vestibular Schwannoma and Psychological Factors Unknown status NCT01743248
42 Vestibular System in Migrainous Vertigo Patients Unknown status NCT00901953
43 NF2 Natural History Consortium Unknown status NCT00004483
44 Longitudinal Study Of The Evoked Compound Action Potential Measured In Children Cochlear Implant Users Completed NCT00725998
45 Optimizing the Ocular Surface Prior to Cataract Surgery Completed NCT02766907 Not Applicable
46 Vestibular Evaluation After Vestibular Schwannoma Treatment Completed NCT03670589
47 Role of Psychiatric Profile in Prehabituated Patients After Vestibular Schwannoma Surgery Completed NCT03638310 Not Applicable
48 Reliability of Functional Outcome Measures in Neurofibromatosis 2 Completed NCT03617276
49 WES of NF2-associated in Comparison to Sporadic Vestibular Schwannomas - Correlation With Clinical Data Completed NCT03210285
50 Vertigo Perception and Quality of Life in Patients After Surgical Treatment of Vestibular Schwannoma Completed NCT02963896 Not Applicable gentamicin

Search NIH Clinical Center for Vestibulocochlear Nerve Disease

Cochrane evidence based reviews: vestibulocochlear nerve diseases

Genetic Tests for Vestibulocochlear Nerve Disease

Anatomical Context for Vestibulocochlear Nerve Disease

MalaCards organs/tissues related to Vestibulocochlear Nerve Disease:

42
Brain, Testes, Endothelial

Publications for Vestibulocochlear Nerve Disease

Articles related to Vestibulocochlear Nerve Disease:

# Title Authors Year
1
Facial and vestibulocochlear nerve disease in six horses. ( 6643213 )
1983

Variations for Vestibulocochlear Nerve Disease

Expression for Vestibulocochlear Nerve Disease

Search GEO for disease gene expression data for Vestibulocochlear Nerve Disease.

Pathways for Vestibulocochlear Nerve Disease

GO Terms for Vestibulocochlear Nerve Disease

Biological processes related to Vestibulocochlear Nerve Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 central nervous system neuron differentiation GO:0021953 8.62 CACNA1A LMX1A

Molecular functions related to Vestibulocochlear Nerve Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 metal ion binding GO:0046872 9.02 CACNA1A LMX1A PIR RTEL1 SALL1

Sources for Vestibulocochlear Nerve Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....